SCHEMBL9907408

SCHEMBL9907408

COC(=O)c1ccc2nccc(-c3ccc(F)c(C)c3)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.45
HTT P42858 1/20 0.45
TGFBR1 P36897 1/20 0.43
TLR8 Q9NR97 3/20 0.42
SLC2A1 P11166 1/20 0.41
ERN1 O75460 1/20 0.41
PIK3CA P42336 2/20 0.40
PIK3CD O00329 1/20 0.40
MTOR P42345 1/20 0.40
CREBBP Q92793 1/20 0.40
KDR P35968 1/20 0.40
DYRK1A Q13627 1/20 0.40
KDM4E B2RXH2 2/20 0.39
KDM6B O15054 1/20 0.39
KDM5C P41229 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM2A Q9Y2K7 1/20 0.39
KDM3A Q9Y4C1 1/20 0.39
BRD4 O60885 1/20 0.38
CCNT1 O60563 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907409 0.91 ALOX15 (0.45) ALOX15HTTTGFBR1TLR8SLC2A1
SCHEMBL9907411 0.87 MPL (0.45) TLR8PIK3CAKDM4EALDH1A1GAA
SCHEMBL9909221 0.85 AAK1 (0.43) ALOX15HTTTGFBR1ERN1CREBBP
SCHEMBL9909224 0.83 KIF11 (0.49) ALOX15HTTTGFBR1ERN1CREBBP
SCHEMBL9907346 0.81 HTT (0.47) ALOX15HTTTGFBR1DYRK1AKDM4E
SCHEMBL9907469 0.81 TGFBR1 (0.48) ALOX15HTTTGFBR1PIK3CACREBBP
SCHEMBL9907819 0.81 HTR5A (0.53)
SCHEMBL29245472 0.80 PIK3CA (0.51) ALOX15HTTTGFBR1PIK3CAPIK3CD
SCHEMBL9907325 0.80 ALOX15 (0.55) ALOX15HTTTGFBR1PIK3CAKDM4E
SCHEMBL9907399 0.80 ALOX15 (0.46) ALOX15HTTTGFBR1KDRDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E ALOX15 1101/4885HTT 970/4885TGFBR1 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.